Alvotech and LOTTE Biologics Sign US Manufacturing Deal for Biosimilars
Alvotech and LOTTE Biologics have agreed to produce multiple biosimilar products at a New York facility, expanding global supply capacity.
Alvotech and LOTTE Biologics have entered into a manufacturing agreement that will see multiple biosimilar products produced at LOTTE Biologics' facility in Syracuse, New York, the companies announced. The collaboration is designed to bolster global supply of biosimilar medicines, which offer lower-cost alternatives to brand-name biologic drugs.
The Syracuse plant serves as the US production hub under the deal, positioning both companies to meet growing demand for biosimilars in North American and international markets. Biosimilars have become an increasingly important segment of the pharmaceutical industry as healthcare systems worldwide seek to reduce drug costs without sacrificing clinical efficacy.
Read more Black Hills Corp. Signs Long-Term Deal to Power Google Data Center in Wyoming →
Alvotech, a global biopharmaceutical company focused exclusively on biosimilar development and manufacturing, brings pipeline depth to the partnership. LOTTE Biologics, a contract development and manufacturing organization, provides the US-based production infrastructure that can help Alvotech navigate domestic supply chain considerations and regulatory pathways.
The agreement underscores a broader industry trend of biosimilar developers securing domestic manufacturing capacity amid persistent concerns about supply chain resilience and geopolitical risk. A US-based facility also positions the partners favorably as policymakers increasingly scrutinize pharmaceutical supply chains for reliance on foreign production.
Continue reading at GlobeNewswire - Industry News on Financial Services.
